Form 4: AVITA Medical Director Cook Receives Equity Awards

AVITA Medical Director Jeremy Curnock Cook was granted 22,214 restricted stock units and 16,133 stock options, contingent on stockholder approval obtained on June 3, 2026.

Summary

• Jeremy Curnock Cook, a Director of AVITA Medical, Inc. (RCEL), was granted 22,214 Restricted Stock Units (RSUs) and 16,133 stock options.
• The RSUs represent a contingent right to receive one share of Common Stock per unit and are subject to time-based vesting, vesting 12 months after the January 20, 2026 grant date.
• The stock options have an exercise price of $3.77, equal to the closing price on Nasdaq on the January 20, 2026 grant date, and become exercisable on January 20, 2027, expiring on January 20, 2036.
• Both the RSU and stock option grants were approved by the Board of Directors on January 5, 2026, with a grant date of January 20, 2026, but were contingent on stockholder approval, which was obtained on June 3, 2026.
• Following these transactions, Jeremy Curnock Cook beneficially owns 62,050 shares of Common Stock (including unvested RSUs) and 16,133 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard corporate governance practices for director compensation and aligning director interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The grants align the director's interests with those of shareholders through equity ownership.
• The stock options have an exercise price of $3.77, which was the closing price on the grant date, indicating a standard grant.

Future Outlook

The vesting schedule for the restricted stock units and the exercisability of the stock options indicate future equity ownership for the director, aligning long-term incentives.

Industry Context

StockSavvy.ai notes that equity awards such as Restricted Stock Units and stock options are standard components of director compensation packages in the biotechnology and medical device industries. These awards are designed to align the interests of directors with those of shareholders by providing a direct stake in the company's long-term performance.

Comparison to Industry Standards

• Director compensation practices, including the use of equity awards like RSUs and stock options, are common across publicly traded companies, particularly in growth-oriented sectors such as medical technology.
• For instance, similar structures are observed in companies like Integra LifeSciences Holdings Corporation or CONMED Corporation, where non-executive directors receive a mix of cash and equity to incentivize long-term value creation.
• The specific grant amounts are typically benchmarked against peer groups to ensure competitive compensation while managing potential dilution.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Jeremy Curnock Cook, a director, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares upon RSU vesting and option exercise, but also improved alignment of director incentives with shareholder value creation.

Next Steps

• Vesting of 22,214 Restricted Stock Units on January 20, 2027.
• Stock options becoming exercisable on January 20, 2027.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Awards, Jeremy Curnock Cook, Corporate Governance